|1.||Boyko, Valentina: 30 articles (12/2010 - 01/2002)|
|2.||Behar, Solomon: 27 articles (03/2009 - 01/2002)|
|3.||Tenenbaum, Alexander: 21 articles (01/2014 - 05/2002)|
|4.||Fisman, Enrique Z: 19 articles (01/2014 - 05/2002)|
|5.||Tanne, David: 19 articles (03/2009 - 01/2002)|
|6.||Goldbourt, Uri: 18 articles (02/2013 - 01/2002)|
|7.||Goldenberg, Ilan: 13 articles (01/2014 - 10/2003)|
|8.||Adler, Yehuda: 13 articles (01/2009 - 01/2002)|
|9.||Haim, Moti: 12 articles (02/2013 - 01/2002)|
|10.||Benderly, Michal: 12 articles (02/2013 - 01/2006)|
01/01/1998 - "This unique characteristic of bezafibrate, which possesses both a hypolipidemic effect and antioxidant activity, may be beneficial in preventing vascular complications in hyperlipidemia."
09/01/1988 - "These results suggest that bezafibrate is effective in the treatment of hyperlipidemia."
04/16/2000 - "First line treatment with bezafibrate, or statins in some with combined hyperlipidemia, had failed. "
05/01/2010 - "Bezafibrate retard is a commonly used medication for hyperlipidemia. "
11/01/2000 - "Bezafibrate is naturally used for hyperlipidemia worldwide. "
|2.||Biliary Liver Cirrhosis (Primary Biliary Cirrhosis)
02/01/2005 - "The therapeutic efficacy of bezafibrate, a hypolipidemic drug, has been shown in patients with primary biliary cirrhosis (PBC) in some pilot studies; however, little is known regarding the mechanism of action of bezafibrate in PBC. "
02/01/2005 - "Therapeutic efficacy of decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis."
04/01/2002 - "Is bezafibrate histologically effective for primary biliary cirrhosis?"
01/01/2002 - "Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy."
01/01/2012 - "We need more randomised clinical trials on the effects of bezafibrate on primary biliary cirrhosis with low risks of systematic errors and random errors."
01/01/2012 - "In clinical trials bezafibrate was highly effective for cardiovascular risk reduction in patients with metabolic syndrome and atherogenic dyslipidemia. "
01/01/2010 - "Bezafibrate may be effective for ovulation induction in CC-resistant PCOS patients with dyslipidemia."
06/08/2005 - "Bezafibrate effectively ameliorates atherogenic dyslipidemia by reducing remnants and small LDL as well as by increasing HDL particles in hypertriglyceridemic subjects."
01/29/2008 - "Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial."
07/01/2013 - "Thirty-two essential hypertensive patients with dyslipidemia (6 men and 26 women, mean age 65±8 years old) were assigned to a control period and a bezafibrate period (200 mg twice daily) for 8 weeks each in a randomized crossover manner. "
12/06/1980 - "[The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types]."
06/29/1985 - "These findings show that bezafibrate affords safe and effective long-term treatment of patients with hyperlipoproteinemia."
01/01/1990 - "Long lasting efficacy of Bezalip retard on the regulation of lipid levels after discontinuation of administration in patients with hyperlipoproteinemia."
06/29/1985 - "Bezafibrate, a new hypolipidemic agent, was evaluated in a single blind, placebo-controlled study lasting 14 months to 3 years in 40 patients with primary hyperlipoproteinemia of various types (23 patients with type II, 15 with type IV and 2 with type V). "
01/01/1992 - "The efficacy and safety of bezafibrate were evaluated in 83 patients with type IIa, IIb, or IV hyperlipoproteinemia. "
11/01/2011 - "Our results indicate that bezafibrate is superior to omega-3 fatty acid in inhibiting systemic inflammation and lymphocyte secretory function."
10/01/2008 - "Bezafibrate improved hepatic steatosis and potently prevented inflammation, oxidative stress, HSC activation, and fibrogenesis in the liver. "
06/08/2005 - "None of inflammation makers showed significant change by bezafibrate. "
04/01/2003 - "Our results suggest that bezafibrate reduces hyperlipidemia, inhibits pancreatic inflammation, and prevents pancreatic degeneration in obese and diabetic OLETF rats."
07/01/2011 - "Our study suggests that bezafibrate is superior to omega-3 fatty acids in reducing systemic inflammation and in producing monocyte-suppressing effects. "
|1.||Ursodeoxycholic Acid (Urso)
|6.||Fibric Acids (Fibrates)
|1.||Renal Dialysis (Hemodialysis)
|2.||Highly Active Antiretroviral Therapy (HAART)
|3.||Hematopoietic Stem Cell Transplantation
|4.||Heart Transplantation (Grafting, Heart)